WHO advisers recommend 3rd COVID vaccine dose for highest-risk groups.
WHO advisers recommend 3rd COVID vaccine dose for highest-risk groups – CIDRAP See also: WHO advises additional COVID shot for immunocompromised people – Reuters
The post WHO advisers recommend 3rd COVID vaccine dose for highest-risk groups. appeared first on Links Medicus.
Cluster RCT: An antimicrobial stewardship intervention safely reduced the use of broad-spectrum antibiotics among patients hospitalized with moderately severe community-acquired pneumonia.
Narrow-spectrum antibiotics for community-acquired pneumonia in Dutch adults (CAP-PACT): a cross-sectional, stepped-wedge, cluster-randomised, non-inferiority, antimicrobial stewardship intervention trial – The Lancet Infectious Diseases (link to abstract – $ for full-text)
The post Cluster RCT: An antimicrobial stewardship intervention safely reduced the use of broad-spectrum antibiotics among patients hospitalized with moderately severe community-acquired pneumonia. appeared first on Links Medicus.
How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.
How antiviral pill molnupiravir shot ahead in the COVID drug hunt – Nature Related: What we know — and don’t know — about Merck’s new Covid-19 pill. [Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with […]
The post How antiviral pill Molnupiravir shot ahead in the COVID drug hunt. appeared first on Links Medicus.
Why easing COVID restrictions could prompt a fierce flu rebound – “As pandemic restrictions ease, other respiratory viruses are returning in unexpected ways”.
Why easing COVID restrictions could prompt a fierce flu rebound – Nature
The post Why easing COVID restrictions could prompt a fierce flu rebound – “As pandemic restrictions ease, other respiratory viruses are returning in unexpected ways”. appeared first on Links Medicus.
D-Dimer testing for the exclusion of pulmonary embolism has limited clinical utility among hospitalized patients with COVID-19 – most patients with or without pulmonary embolism have increased levels.
D-Dimer Testing for the Exclusion of Pulmonary Embolism Among Hospitalized Patients With COVID-19 – JAMA Network Open Commentary: D-Dimer Level Not Useful for Ruling Out PE in COVID-19 Patients – HealthDay
The post D-Dimer testing for the exclusion of pulmonary embolism has limited clinical utility among hospitalized patients with COVID-19 – most patients with or without pulmonary embolism have increased levels. appeared first on Links Medicus.
RCT: No benefit from antithrombotic therapy (aspirin or apixaban) in outpatients with clinically stable symptomatic COVID-19.
Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial – JAMA Editorial: Antithrombotic Therapy for Outpatients With COVID-19: Implications for Clinical Practice and Future Research – JAMA Commentary on Twitter Data do not support the use of aspirin or apixaban in the outpatient setting […]
The post RCT: No benefit from antithrombotic therapy (aspirin or apixaban) in outpatients with clinically stable symptomatic COVID-19. appeared first on Links Medicus.
Heart-inflammation risk from Pfizer COVID vaccine is very low.
Heart-inflammation risk from Pfizer COVID vaccine is very low – Nature Original studies: Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons. Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine […]
The post Heart-inflammation risk from Pfizer COVID vaccine is very low. appeared first on Links Medicus.
Bioethics | The Trolley Problem and Vaccinating Young People Against COVID-19.
The Trolley Problem and Vaccinating Young People Against COVID-19 – Science-Based Medicine
The post Bioethics | The Trolley Problem and Vaccinating Young People Against COVID-19. appeared first on Links Medicus.
RCT: Therapeutic-dose heparin superior to standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19.
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial – JAMA Internal Medicine Invited commentary: Anticoagulant Therapy in Patients Hospitalized With COVID-19 – JAMA Internal Medicine Related studies (some conflicting results) Another meta-analysis suggests standard-dose prophylactic anticoagulation is the […]
The post RCT: Therapeutic-dose heparin superior to standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19. appeared first on Links Medicus.
Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.
Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England – Eurosurveillance Related: RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine. Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination. Heterologous Oxford–AstraZeneca and Moderna Vaccination induce […]
The post Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination. appeared first on Links Medicus.